<unk>  was introduced in 1967, as a major addition to the cocktail-drug treatment of tuberculosis and inactive meningitis, along with pyrazinamide,<unk> , ethambutol and streptomycin ("PIERS"). It requires a prescription in North America. It must be administered regularly daily for several months without break; otherwise, the risk of drug-resistant tuberculosis is greatly increased. In fact, this is the primary reason it is used in tandem with the three aforementioned drugs, particularly<unk> . This is also the primary motivation behind directly observed therapy for tuberculosis.<unk>  also known as isonicotinylhydrazine (INH), is an organic compound that is the first-line medication in prevention and treatment of tuberculosis. The compound was first synthesized in the early 20th century, but its activity against tuberculosis was first reported in the early 1950s, and three pharmaceutical companies attempted unsuccessfully to simultaneously patent the drug (the most prominent one being Roche, which launched its version, Rimifon, in 1952). The drug was first tested at Many Farms, a Navajo community, due to the Navajo reservation's dire tuberculosis problem and the fact that the population was naïve with respect to streptomycin, the main tuberculosis treatment at the time. With the introduction of<unk> , a cure for tuberculosis was first considered reasonable.
Rifampin isoniazid
Ethambutol
Pyrazinamide
Safinamide
Isoniazid 
Monoxerutin
Rifabutin
Voriconazole 